Transitioning a patient from injectable opioid agonist therapy to sublingual buprenorphine/naloxone for the treatment of opioid use disorder using a microdosing approach. Issue 3 (25th March 2020)

• Record Type: Journal Article
• Authors: Caulfield, Mackenzie Duncan Gregory; Brar, Rupinder; Sutherland, Christy; Nolan, Seonaid
• Is Part Of: BMJ case reports. Volume 13:Issue 3(2020)
• Publication Date: 2020-03-25
• Subjects: psychiatry (drugs and medicines) -- drug misuse (including addiction) -- therapeutic indications -- drugs misuse (including addiction) -- impulse control disorders; Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2019-233715
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : In the wake of North America's opioid crisis, access to evidence-based treatment for opioid use disorder (OUD) is of critical importance. While buprenorphine/naloxone and methadone are currently indicated as first-line medications for the treatment of OUD, there are a proportion of individuals who do not benefit from these therapies. Recent Canadian guidelines suggest the use of alternate therapies, including slow-release oral morphine or injectable opioid agonist therapy (iOAT) for individuals unsuccessful with either methadone or buprenorphine/naloxone. While the guidelines highlight the need to intensify OUD treatment as disease severity increases, equally important is the consideration for deintensification of treatment (eg, from iOAT to an oral opioid agonist treatment (OAT) option) following successful stabilisation. Literature addressing how best to accomplish this, however, is currently lacking. Accordingly, the case presented here describes a patient that successfully transitions from iOAT to oral buprenorphine/naloxone using a novel induction approach termed microdosing.